Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.

@article{Mitchell2010RanibizumabI,
  title={Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.},
  author={Paul Mitchell and J. F. Korobelnik and Paolo Lanzetta and Frank G. Holz and Christian Pruente and Ursula Schmidt-Erfurth and Yasuo Tano and Sebastian Wolf},
  journal={The British journal of ophthalmology},
  year={2010},
  volume={94 1},
  pages={
          2-13
        }
}
  • Paul Mitchell, J. F. Korobelnik, +5 authors Sebastian Wolf
  • Published in
    The British journal of…
    2010
  • Medicine
  • BACKGROUND Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in legal blindness. Ranibizumab is approved for treating neovascular AMD. However, further guidance is needed to assist ophthalmologists in clinical practice to optimise treatment outcomes. METHODS An international retina expert panel assessed evidence available from prospective, multicentre studies evaluating different ranibizumab treatment schedules (ANCHOR, MARINA… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Topics from this paper.

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 177 CITATIONS, ESTIMATED 48% COVERAGE

    Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration

    VIEW 4 EXCERPTS
    CITES RESULTS & BACKGROUND
    HIGHLY INFLUENCED

    Leitlinien zur Behandlung der feuchten Makuladegeneration

    VIEW 5 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    FILTER CITATIONS BY YEAR

    2009
    2019

    CITATION STATISTICS

    • 11 Highly Influenced Citations

    • Averaged 9 Citations per year from 2017 through 2019